Researchers at a Texas Medical Center have created a better in vitro breast cancer model using 3D bioprinting technology developed by Rainbow Coral Corporation’s joint venture partner, Nano3D Biosciences (n3D).
The ground-breaking 3D bioprinting technology can be used for high-content and high throughput drug screening. The Bio-Assembler is part of n3D’s 3D bioprinting system, and it can be used for magnetically levitating cell cultures for creating a better in vitro model of breast cancer. The in vitro cell heterogeneity of the microenvironment of the tumor could be successfully replicated.
In order to levitate cells, the Bio-Assembler utilizes biocompatible magnetic nanoparticles. When compared to other technologies, the n3D technology enables simpler, more rapid and low-cost method of growing 3D structures.
These results signify a crucial breakthrough in studying cancer cells outside the body and developing new treatments. We at n3D are very proud that the Bio-Assembler, a technology we developed, is being used in critical research such as this important study.
Dr. Glauco Souza, n3D president and chief science office
The data obtained from the study suggested that the 3D in vitro breast tumor model demonstrated significant advantages due to four factors. It was able to form large-sized breast tumor models within a period of 24 hours; it could control the density and composition of tumor cells; the in vivo tumor microenvironment could be mimicked successfully; and the testing of drug efficiency was comparable to that of in vivo tumors.
RBCC and n3D have been raising funds in order to further develop and commercialize the 3D bioprinting technology.
This study has been published in the research journal, Scientific Reports.
References